Building a lasting foundation for precision oncology
While local and regional initiatives address some major barriers, global efforts are needed to make molecularly guided options accessible to all patients.
The CXCR2 antagonist AZD5069 plus enzalutamide is shown to be active in mCRPC
In a phase I/II study, the combination treatment was tolerable in men who had progressed on one novel anti-androgen therapy
The ESMO Global Study on Access to Cancer Medicines shows stark global inequalities
The availability and affordability of a broad range of prescription cancer medicines have been analysed
Positive clinical results for immunotherapy in metastatic/recurrent cervical cancer
Results from two studies shows promise for combination immunotherapy in a population with a high unmet need for new treatments
Survival benefit in two trials of first-line immunotherapy in advanced hepatocellular carcinoma
Encouraging efficacy data with anti-PD1 antibody in combination or as monotherapy
Can telehealth be a genuine replacement for face-to-face healthcare?
In the post-COVID-19 era, there is a need to evaluate the quality, safety and effectiveness of telehealth to deliver cancer care says ESMO Keynote Lecturer Dr Deborah Schrag
Overall survival data further support sacituzumab govitecan in HR+/HER2– metastatic breast cancer
Findings from the TROPiCS-02 trial show an overall survival benefit of sacituzumab govitecan in heavily pre-treated patients but raise questions about its optimal clinical implementation
MONARCH 3: trend for improved overall survival with abemaciclib plus aromatase inhibitor in advanced breast cancer
An interim analysis of phase III data further supports the use of abemaciclib plus non-steroidal aromatase inhibitor in patients with HR+, HER2– advanced breast cancer
LAG3 inhibitors are changing the landscape of immunotherapy
After impressive results were achieved in melanoma, there is now great interest in exploring the potential of dual LAG3/PD-1 inhibition in other tumour types
How to integrate tebentafusp in the checkpoint-based clinical management of patients with uveal melanoma?
Since its approval, tebentafusp is changing the treatment landscape for patients with metastatic uveal melanoma, but many questions remain